PDL BioPharma, Inc.
PDLIV
NASDAQ
Recommendation
Prev Close
--
Volume
--
Avg Vol (90D)
--
Market Cap
--
Dividend & Yield
--
52-Week Range
-- - --
P/E (TTM)
--
EPS (TTM)
| 08/31/2020 | 06/30/2020 | 03/31/2020 | 12/31/2019 | 09/30/2019 | |
|---|---|---|---|---|---|
| Revenue | -- | 5.21M | 6.00M | 8.52M | 8.03M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 5.21M | 6.00M | 8.52M | 8.03M |
| Cost of Revenue | -- | 2.64M | 2.86M | 3.78M | 4.77M |
| Gross Profit | -- | 2.57M | 3.14M | 4.74M | 3.27M |
| SG&A Expenses | -- | 10.96M | 14.12M | 13.30M | 11.61M |
| Depreciation & Amortization | -- | 335.00K | 302.00K | 307.00K | 321.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | 15.40M | 19.14M | 18.63M | 21.00M |
| Operating Income | -- | -10.18M | -13.14M | -10.11M | -12.97M |
| Income Before Tax | -- | -14.01M | -46.24M | 9.59M | -14.95M |
| Income Tax Expenses | -- | -1.08M | -14.47M | 5.54M | -3.14M |
| Earnings from Continuing Operations | -- | -12.93M | -31.77M | 4.05M | -11.81M |
| Earnings from Discontinued Operations | -- | -37.40M | -244.00K | -58.88M | -6.16M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | 357.00K | 288.00K | -60.00K | 182.00K |
| Net Income | -- | -49.97M | -31.72M | -54.89M | -17.78M |
| EBIT | -- | -10.18M | -13.14M | -10.11M | -12.97M |
| EBITDA | -- | -9.49M | -12.33M | -9.24M | -12.04M |
| EPS Basic | -0.43 | -0.43 | -0.26 | -0.46 | -0.16 |
| Normalized Basic EPS | -- | -0.05 | -0.06 | -0.06 | -0.08 |
| EPS Diluted | -0.43 | -0.43 | -0.26 | -0.46 | -0.16 |
| Normalized Diluted EPS | -- | -0.05 | -0.06 | -0.06 | -0.08 |
| Average Basic Shares Outstanding | -- | 115.91M | 122.90M | 118.63M | 112.99M |
| Average Diluted Shares Outstanding | 115.91M | 115.91M | 122.90M | 118.63M | 112.99M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -0.01% | -- |